Search Results - "van der Noordaa, M. E. M."

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure by van der Noordaa, M. E. M., van Duijnhoven, F. H., Straver, M. E., Groen, E. J., Stokkel, M., Loo, C. E., Elkhuizen, P. H. M., Russell, N. S., Vrancken Peeters, M. T. F. D.

“…Background Axillary lymph node dissection (ALND) is frequently performed for node-positive (cN+) breast cancer patients. Combining positron emission…”
Get full text

Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node‐positive breast cancer after neoadjuvant therapy by Koolen, B. B., Donker, M., Straver, M. E., van der Noordaa, M. E. M., Rutgers, E. J. T., Valdés Olmos, R. A., Vrancken Peeters, M. J. T. F. D.

“…Background The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND)…”
Get full text

[18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy by van Loevezijn, Ariane A., Stokkel, Marcel P. M., Donswijk, Maarten L., van Werkhoven, Erik D., van der Noordaa, Marieke E. M., van Duijnhoven, Frederieke H., Vrancken Peeters, Marie-Jeanne T. F. D.

“…Purpose Axillary staging before neoadjuvant systemic therapy in clinically node-positive breast cancer patients with tailored axillary treatment according to…”
Get full text

Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol by van Loevezijn, Ariane A., van der Noordaa, Marieke E. M., Stokkel, Marcel P. M., van Werkhoven, Erik D., Groen, Emma J., Loo, Claudette E., Elkhuizen, Paula H. M., Sonke, Gabe S., Russell, Nicola S., van Duijnhoven, Frederieke H., Vrancken Peeters, Marie-Jeanne T. F. D.

“…Purpose In clinically node-positive (cN+) breast cancer patients, evidence supporting response-guided treatment after neoadjuvant systemic therapy (NST)…”
Get full text

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer by Groen, Emma J., van der Noordaa, Marieke E. M., Schaapveld, Michael, Sonke, Gabe S., Mann, Ritse M., van Ramshorst, Mette S., Lips, Esther H., Vrancken Peeters, Marie-Jeanne T. F. D., van Duijnhoven, Frederieke H., Wesseling, Jelle

“…Purpose The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for…”
Get full text

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study by van Loevezijn, Ariane A., van der Noordaa, Marieke E.M., van Werkhoven, Erik D., Loo, Claudette E., Winter-Warnars, Gonneke A. O., Wiersma, Terry, van de Vijver, Koen K., Groen, Emilie J., Blanken-Peeters, Charlotte F. J. M., Zonneveld, Bas J.G.L., Sonke, Gabe S., van Duijnhoven, Frederieke H., Vrancken Peeters, Marie-Jeanne T. F. D.

“…Background The added value of surgery in breast cancer patients with pathological complete response (pCR) after neoadjuvant systemic therapy (NST) is…”
Get full text

Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience by van der Noordaa, Marieke E. M., Ioan, Ileana, Rutgers, Emiel J., van Werkhoven, Erik, Loo, Claudette E., Voorthuis, Rosie, Wesseling, Jelle, van Urk, Japke, Wiersma, Terry, Dezentje, Vincent, Vrancken Peeters, Marie-Jeanne T. F. D., van Duijnhoven, Frederieke H.

“…Background Many cT3 breast cancer patients are treated with mastectomy, regardless of response to neoadjuvant systemic therapy (NST). We evaluated local…”
Get full text

ASO Author Reflections: Reducing Axillary Lymph Node Dissections in Node-Positive Breast Cancer Patients by van der Noordaa, Marieke E. M., Vrancken Peeters, Marie-Jeanne T. F. D.

Get full text

Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment) by van der Noordaa, M.E.M., van Duijnhoven, F.H., Loo, C.E., van Werkhoven, E., van de Vijver, K.K., Wiersma, T., Winter-Warnars, H.A.O., Sonke, G.S., Vrancken Peeters, M.T.F.D.

“…Improvements in neoadjuvant systemic therapy (NST) for breast cancer patients have led to increasing rates of pathologic complete response (pCR). The MICRA…”
Get full text

The intraoperative assessment of sentinel nodes – Standards and controversies by van der Noordaa, M.E.M., Vrancken Peeters, M.T.F.D., Rutgers, E.J.T.

“…Intraoperative assessment of sentinel lymph nodes (SLNs) has the advantage of allowing breast cancer patients with tumor-positive SLNs to avoid a second…”
Get full text

The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium by van der Noordaa, M E M, Pengel, K E, Groen, E, van Werkhoven, E, Rutgers, E J Th, Loo, C E, Vogel, W, Vrancken Peeters, M J T F D

“…Radioactive Seed Localization with a radioactive iodine-125 seed (RSL) and Radioguided Occult Lesion Localization with 99mTechnetium colloid (ROLL) are both…”
Get full text

Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer by van der Noordaa, M E M, van Duijnhoven, F H, Cuijpers, F N E, van Werkhoven, E, Wiersma, T G, Elkhuizen, P H M, Winter-Warnars, G, Dezentje, V, Sonke, G S, Groen, E J, Stokkel, M, Vrancken Peeters, M T F D

“…The nodal positivity rate after neoadjuvant chemotherapy (ypN+) in patients with clinically node-negative (cN0) breast cancer is low, especially in those with…”
Get full text

Abstract P3-13-02: Breast conserving therapy after neoadjuvant systemic therapy in patients with T3 breast cancer is feasible by van der Noordaa, ME, Vrancken Peeters, M-JM, Ioan, I, Loo, CE, van Urk, J, van Werkhoven, E, Voorthuis, R, Wiersma, T, Groen, E, Rutgers, ET, van Duijnhoven, FH

“…Abstract Background An important advantage of neoadjuvant systemic therapy (NST) in breast cancer patients is down-sizing of the primary tumor. However, many…”
Get full text

Abstract GS5-06: Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment) by Peeters, Marie-Jeanne T.F.D. Vrancken, van Loevezijn, A, van der Noordaa, M EM, van Duijnhoven, F H, Loo, C E, van Werkhoven, E, van de Vijver, K K, Wiersma, T, Winter-Warnars, H AO, Sonke, G S, Blanken, C., Zonnevels, B.

“…Abstract Background and Objectives: Improvements in neoadjuvant systemic therapy (NST) for breast cancer patients have led to increasing rates of pathologic…”
Get full text

Abstract OT2-01-04: Towards omitting breast cancer surgery in patients with pathologic complete response after neoadjuvant systemic therapy: The MICRA trial (minimally invasive complete response assessment) by van der Noordaa, ME, van Duijnhoven, FH, Loo, CE, van Loevezijn, A, van Werkhoven, E, van de Vijver, KK, Wiersma, T, Winter-Warnars, HA, Sonke, GS, Vrancken Peeters, M-JT

“…Abstract Background Improvements in neoadjuvant systemic therapy (NST) for breast cancer patients have led to increasing rates of pathologic complete response…”
Get full text

Abstract PD4-04: Role of breast MRI in predicting pathologically negative nodes after neoadjuvant chemotherapy in cN0 patients in the I-SPY2 trial by van der Noordaa, ME, Esserman, L, Yau, C, Mukhtar, R, Price, E, Hylton, N, Abe, H, Wolverton, D, Crane, EP, Ward, KA, Nelson, M, Niell, BL, Oh, K, Brandt, KR, Bang, DH, Ojeda-Fournier, H, Eghtedari, M, Sheth, PA, Bernreuter, WK, Umphrey, H, Rosen, MA, Dogan, B, Yang, W, Joe, B, van 't Veer, L, Hirst, G, Lancaster, R, Wallace, A, Alvaredo, M, Symmans, F, Asare, S, Boughey, JC

“…Abstract Background In clinically node-negative (cN0) breast cancer patients with triple negative (TN) and HER2+ disease and breast pathological complete…”
Get full text

Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore by van der Noordaa, Marieke EM, Yau, Christina, Shad, Sonal, Osdoit, Marie, Steenbruggen, Tessa G, de Croze, Diane, Hamy, Anne-Sophie, Lae, Marick, Reyal, Fabien, Del Monte-Millán, Maria, Martin, Miguel, Tarruella, Sara Lopez, Boughey, Judy C, Goetz, Matthew, Hoskin, Tanya, Gould, Rebecca, Valero, Vincent, Sonke, Gabe, van Seijen, Maartje, Wesseling, Jelle, Bartlett, John, Edge, Stephan, Kim, Mi-Ok, Abraham, Jean, Caldas, Carlos, Earl, Helena, Provenzano, Elena, Sammut, Stephen-John, Cameron, David, Graham, Ashley, Hall, Peter, MacKintosh, Lorna, Fan, Fang, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela, Dunn, Janet, Hiller, Louise, Hayward, Larry, Thomas, Jeremy, Cole, Kimberley, Pusztai, Lajos, van 't Veer, Laura, Symmans, Fraser, Esserman, Laura

“…Abstract Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer is associated with improved…”
Get full text